Home › Psoriasis › NCT05744466

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

A Real-world, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib Versus Apremilast in Adults With Plaque Psoriasis - North American Region

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Have been diagnosed with plaque psoriasis by a dermatologist
* Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
* Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes

Exclusion Criteria:

* Participation (current or planned) in an interventional clinical trial (does not include observational registry or study)
* Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history

About the study

The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.

What is being tested

• Deucravacitinib (drug)
• Apremilast (drug)

Sponsor: Bristol-Myers Squibb · Participants: 1,500 · Started: Sep 30, 2022

Contact the study team

• BMS Study Connect Contact Center www.BMSStudyConnect.com · Phone: 855-907-3286

Official record on ClinicalTrials.gov — NCT05744466

Locations in the U.S.

Conditions

• Psoriasis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.